Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritisResearch in context
Xiaojuan He,
Jin Liu,
Chao Liang,
Shaikh Atik Badshah,
Kang Zheng,
Lei Dang,
Baosheng Guo,
Defang Li,
Cheng Lu,
Qingqing Guo,
Danping Fan,
Yanqin Bian,
Hui Feng,
Lianbo Xiao,
Xiaohua Pan,
Cheng Xiao,
BaoTing Zhang,
Ge Zhang,
Aiping Lu
Affiliations
Xiaojuan He
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Jin Liu
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China
Chao Liang
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China
Shaikh Atik Badshah
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China
Kang Zheng
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Lei Dang
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China
Baosheng Guo
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China
Defang Li
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China
Cheng Lu
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Qingqing Guo
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Danping Fan
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
Yanqin Bian
Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital/Shanghai University of TCM, Shanghai, China
Hui Feng
Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital/Shanghai University of TCM, Shanghai, China
Lianbo Xiao
Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital/Shanghai University of TCM, Shanghai, China
Xiaohua Pan
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Department of Orthopaedics and Traumatology, Bao-an Hospital Affiliated to Southern Medical University & Shenzhen 8th People Hospital, Shenzhen, China
Cheng Xiao
Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China
BaoTing Zhang
School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
Ge Zhang
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China; Corresponding author at: Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Aiping Lu
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; Institute of Precision Medicine and Innovative Drug Discovery, Hong Kong Baptist University, Hong Kong, China; School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Corresponding author at: Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Background: Osteoblasts participating in the inflammation regulation gradually obtain concerns. However, its role in joint inflammation of rheumatoid arthritis (RA) is largely unknown. Here, we investigated the role of osteoblastic pleckstrin homology domain-containing family O member 1 (PLEKHO1), a negative regulator of osteogenic lineage activity, in regulating joint inflammation in RA. Methods: The level of osteoblastic PLEKHO1 in RA patients and collagen-induced arthritis (CIA) mice was examined. The role of osteoblastic PLEKHO1 in joint inflammation was evaluated by a CIA model and a K/BxN serum-transfer arthritis (STA) model which were induced in osteoblast-specific Plekho1 conditional knockout mice and mice expressing high Plekho1 exclusively in osteoblasts, respectively. The effect of osteoblastic PLEKHO1 inhibition was explored in a CIA mice model and a non-human primate arthritis model. The mechanism of osteoblastic PLEKHO1 in regulating joint inflammation were performed by a series of in vitro studies. Results: PLEKHO1 was highly expressed in osteoblasts from RA patients and CIA mice. Osteoblastic Plekho1 deletion ameliorated joint inflammation, whereas overexpressing Plekho1 only within osteoblasts exacerbated local inflammation in CIA mice and STA mice. PLEKHO1 was required for TRAF2-mediated RIP1 ubiquitination to activate NF-κB for inducing inflammatory cytokines production in osteoblasts. Moreover, osteoblastic PLEKHO1 inhibition diminished joint inflammation and promoted bone formation in CIA mice and non-human primate arthritis model. Conclusions: These data strongly suggest that the highly expressed PLEKHO1 in osteoblasts contributes to joint inflammation in RA. Targeting osteoblastic PLEKHO1 may exert dual therapeutic action of alleviating joint inflammation and promoting bone formation in RA. Keywords: Osteoblast, PLEKHO1, Rheumatoid arthritis, Inflammation, Bone formation